Products
Online Inquiry
Datasheet
5-HT1A partial agonist (Ki = 9.3–29.5 nM); anxiolytic in vivo; affects dopaminergic, noradrenergic, and GABA-benzodiazepine receptor systems.
- Home
- Solutions
- By Disease
- Systemic Mitochondrial Disease
- Alpers Disease
- Barth Syndrome
- Carnitine Deficiency
- Creatine Deficiency Syndromes
- Co-Enzyme Q10 Deficience
- Friedreich’s Ataxia
- Kearns-Sayre Syndrome
- Lactic Acidosis
- Leigh Syndrome
- Mitochondrial DNA Depletion Syndrome
- MELAS Syndrome
- Multiple Mitochondrial Dysfunction Syndrome
- Short-Chain Acyl-CoA Dehydrogenase Deficiency
- Thymidine Kinase 2 Deficiency
- Mitochondrial Neurogastrointestinal Encephalopathy
- Organ-specific Mitochondrial Diseases
- Systemic Mitochondrial Disease
- By Applications
- Mitochondrial Disease Diagnostics Service
- Therapeutics Development Services for Mitochondrial Diseases
- Mitochondrial Disease Target Development & Identification Service
- Mitochondrial Disease Model Development Service
- Drug Development Service for Mitochondrial Diseases
- In Vitro Mitochondrial Analysis Service
- In Vivo Mitochondrial Fission and Fusion Analysis
- By Molecular Type
- By Disease
- Products
- Mitochondrial Isolation Reagents & Kits
- Mitochondrial Staining Reagents & Kits
- Mitochondrial Disease Diagnostic Reagents & Kits
- Biochemical Inhibitors & Activators
- Mitochondrial Specific Antibodies
- Mitochondrial Recombinant Proteins
- Mitochondria Related Peptides
- Natural Products Targeting Mitochondria
- Resource
- About Us
- Contact Us
- Careers